In a post‑myocardial infarction patient who is asymptomatic, compliant with medications, has blood pressure 136/89 mmHg, total cholesterol 5.0 mmol/L (upper limit of normal), LDL cholesterol at the upper limit of normal, and HDL cholesterol at the lower limit of normal, what is the next best step in management?

Start Statin Therapy Immediately

This post-myocardial infarction patient requires immediate initiation of high-intensity statin therapy, making Option A (Start statin) the correct answer. The patient's LDL cholesterol at the upper limit of normal is unacceptable after MI—the target is LDL-C <1.4 mmol/L (<55 mg/dL), representing a greater than 50% reduction from baseline 1.

Why Statin Therapy is Mandatory

After myocardial infarction, patients are at very high cardiovascular risk and require aggressive lipid-lowering therapy regardless of baseline cholesterol levels. The 2024 International Lipid Expert Panel guidelines explicitly state that post-MI patients need:

• Target LDL-C <1.4 mmol/L (<55 mg/dL) 1
• High-intensity statin therapy with either atorvastatin 40-80 mg or rosuvastatin 20-40 mg 1
• Treatment should begin immediately during hospitalization and continue indefinitely 1

This patient's current LDL at the "upper limit of normal" (approximately 3.4-4.1 mmol/L or 130-160 mg/dL) is dangerously elevated for someone post-MI. Even "normal" cholesterol levels are inadequate after MI—the goal is intensive reduction to prevent recurrent events, stroke, and cardiovascular death 1.

The Treatment Algorithm

Step 1: Initiate high-intensity statin immediately:

• Atorvastatin 40-80 mg daily, OR
• Rosuvastatin 20-40 mg daily 1

Step 2: Reassess lipid profile at 4-6 weeks:

• If LDL-C remains >1.4 mmol/L, add ezetimibe 10 mg 1
• Do not delay—immediate escalation is critical 1

Step 3: If still not at goal after another 4-6 weeks:

• Add PCSK9 inhibitor (alirocumab, evolocumab) or inclisiran 1

Why Not Fibrate?

Fibrates primarily target triglycerides and are not indicated for post-MI secondary prevention when LDL cholesterol is the primary concern 1. Statins reduce cardiovascular mortality and recurrent MI; fibrates do not have this evidence base in post-MI patients.

Why "No Further Management" is Wrong

Doing nothing condemns this patient to significantly elevated risk of:

• Recurrent myocardial infarction
• Stroke
• Cardiovascular death
• Need for repeat revascularization 1, 2

Real-world data shows that patients not achieving LDL-C <1.4 mmol/L have substantially higher rates of major adverse cardiovascular events 3, 2. The number needed to treat to prevent one event by achieving target LDL-C is approximately 115—highly favorable for secondary prevention 3.

Critical Pitfalls to Avoid

Pitfall #1: Assuming "normal" cholesterol is acceptable post-MI. It is not. Post-MI patients require LDL-C levels far below population norms 1.

Pitfall #2: Delaying statin initiation. Treatment should have been started during the index MI hospitalization 1.

Pitfall #3: Using low or moderate-intensity statins. Only high-intensity statins (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) are appropriate 1.

Pitfall #4: Failing to reassess and escalate therapy. Most patients require combination therapy (statin + ezetimibe) to reach goal 1, 2, 4.

Additional Considerations

The patient's blood pressure of 136/89 mmHg also warrants attention and should be treated to <130/80 mmHg with beta-blockers and ACE inhibitors, which are also indicated post-MI 5. However, the lipid management takes priority in answering this specific question about the "next best step."